Clinical trials: Pancreatic Cancer Stage I
Pancreatic Cancer
Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
The main purpose of this study is to find out the dose of enzalutamide that can be safely given with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer.
- Trial name
- NCT02138383
- Testing
- Enzalutamide, Gemcitabine, Nab-paclitaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-colorectal Cancer, Pancreatic Cancer
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
RATIONALE: Monoclonal antibodies, such as maytansinoid DM4-conjugated humanized monoclonal antibody huC242, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00352131
- Testing
- HuC242-DM4
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunoGen, Inc.
Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma
Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection
Pancreatic cancer represents the most lethal of the common malignancies with a 5-year survival rate of less than 5%. For patients who are eligible for potentially curative resection, despite mortality and morbidity rates after…
- Conditions
- Stage IA Pancreatic Adenocarcinoma, Stage IB Pancreatic Adenocarcinoma, Stage IIA Pancreatic Adenocarcinoma, Stage IIB Pancreatic Adenocarcinoma
- Trial name
- NCT02005419
- Testing
- Gemcitabine, Metformin
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xian-Jun Yu
Cholangiocarcinoma, Colorectal Cancer
TCR1188-ABC Cells in KRAS-mutated Cancers
This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1188-ABC cells in patients with KRAS-mutated cancers.
- Conditions
- Cholangiocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma
- Trial name
- NCT07594067
- Testing
- TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pennsylvania
Gastrointestinal Tumor
Phase I Trial of Combination of FOLFIRI and SOM 230
This is a single-arm, open-label, phase I study of combination therapy with SOM 230 and FOLFIRI. We will utilize a sequential dose-escalation design to define the maximum tolerated dose (MTD) of SOM 230 when combined with…
- Trial name
- NCT01434069
- Testing
- SOM230C LAR, FOLFIRI Infusion
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
This phase I/II trial tests the effect of pegcetacoplan in combination with oxaliplatin, irinotecan, leucovorin, and fluorouracil (mFOLFIRINOX) in treating patients with pancreatic ductal adenocarcinoma (PDAC) that has spread…
- Trial name
- NCT07214298
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Roswell Park Cancer Institute
Pancreatic Cancer
Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
The purposes of this study are to: Evaluate the safety and toxicity of tolfenamic acid when used with gemcitabine and radiation therapy in patients with locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT02159248
- Testing
- Tolfenamic acid + gemcitabine + radiation
- Where
- United States
- Sponsor
- Orlando Health, Inc.
Esophageal Cancer, Gastric Cancer
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in…
- Conditions
- Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT06500052
- Testing
- BL-M17D1
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Pancreatic Cancer
Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, epirubicin hydrochloride, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping…
- Trial name
- PACT-15 (NCT01150630)
- Testing
- capecitabine, cisplatin, epirubicin
- Where
- Italy
- Volunteers
- 98 people
- Sponsor
- IRCCS San Raffaele
Brain and Central Nervous System Tumors, Breast Cancer
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
RATIONALE: Radiolabeled drugs such as yttrium Y 90 SMT 487 can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
- Trial name
- NCT00006368
- Testing
- yttrium Y 90-edotreotide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
Adrenocortical Carcinoma, Breast Cancer
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer
- Trial name
- NCT00436410
- Testing
- colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Stage IV Pancreatic Cancer
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
This randomized phase I/II trial is studying the side effects and best dose of monoclonal antibody therapy when given together with gemcitabine hydrochloride and erlotinib hydrochloride and to see how well they work compared with…
- Trial name
- NCT00617708
- Testing
- cixutumumab, erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 146 sites in United States
- Volunteers
- 134 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)
The purpose of this study is to determine the recommended phase 2 dose (RP2D) of the combination of lonsurf, gemcitabine and nab-paclitaxel in Pancreatic ductal adenocarcinoma (PDAC)
- Trial name
- NCT04046887
- Testing
- Lonsurf, Gemcitabine, Nab-Paclitaxel
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Patrick Joseph Loehrer Sr.
Pancreatic Cancer, Cancer
Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
This is a phase I trial to determine the maximum tolerated dose of carbon ion radiotherapy for the treatment of locally advanced, unresectable, pancreatic cancer.
- Trial name
- NCT03403049
- Testing
- Carbon Ion, Gemcitabine + Cisplatin, Gemcitabine + Capecitabine
- Where
- 2 sites in United States, China
- Volunteers
- 14 people
- Sponsor
- Montefiore Medical Center
Pancreatic Cancer
Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer
Rational: White blood cells that have been treated with carcinoembryonic antigen peptide-1 may help the body build an immune response to and kill tumor cells that express CEA.
- Trial name
- NCT00003434
- Testing
- carcinoembryonic antigen peptide 1, hepatitis B antigen peptide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Duke University
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors
This phase I trial studies the side effects and best dose of SOR-C13 in treating patients with solid tumors that have spread to other places in the body (advanced) and does not respond to treatment.
- Conditions
- Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma
- Trial name
- NCT03784677
- Testing
- TRPV6 Calcium Channel Inhibitor SOR-C13
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Neoplasms
Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
<Part I - Phase I trial> The phase I clinical trial is to identify the MTD (Maximum Tolerated Dose) and DLT (Dose Limiting Toxicity) of CG200745 PPA in combination use of Gemcitabine and Erlotinib.
- Trial name
- NCT02737228
- Testing
- CG200745 PPA, Gemcitabine, Erlotinib
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- CrystalGenomics, Inc.
Pancreatic Neoplasms
Ketogenic Diet With Concurrent Chemoradiation for Pancreatic Cancer
This study investigates if using a very low carbohydrate diet during combined chemotherapy and radiation therapy is safe and if it can be tolerated by patients.
- Trial name
- KETOPAN (NCT01419483)
- Testing
- Ketogenic diet
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Iowa
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors
This phase I trial is studying the side effects and best dose of sunitinib and gemcitabine in treating patients with pancreatic cancer or other solid tumors.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00462553
- Testing
- sunitinib malate, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Breast Cancer
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer
- Trial name
- NCT00004095
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University